Wednesday, 28 October 2026

Product News

Lilly Receives European Marketing Authorization for tirzepatide in KwikPen® Presentation for Two Indications

Eli Lilly and Company announced that the European Commission (EC) granted marketing authorization (MA) on 19 April 2024 for tirzepatide

By Danielle Norton Updated 2 min read
Tirzepatide ABEMACICLIB

Eli Lilly and Company announced that the European Commission (EC) granted marketing authorization (MA) on 19 April 2024 for tirzepatide (Mounjaro®) solution for injection in a multi-dose KwikPen® presentation, for two indications:

– as monotherapy when metformin is considered inappropriate due to intolerance or contraindications

For verified healthcare professionals

Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.

Register for free Log in

Related stories

Join the conversation

Comments are open to registered members. Log in or register to share your thoughts on this article.

Log in to comment Register for free